FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2547932707> ?p ?o ?g. }

• W2547932707 abstract "The strongest CD8+ T cell responses ever recorded in humans occur as a result of infection by the Epstein-Barr Virus (EBV). Following a massive CD8+ T cell response during acute EBV infection, ∼5.5% of the total CD8+ T cell repertoire in blood is thereafter committed to the life-long suppression of viral replication. The key to this response is the EBV Latent Membrane Protein-1 (LMP1) which functions as a constitutively activated form of the CD40 receptor. LMP1 consists of an N-terminal domain that clusters in cell membranes and a C-terminal domain that engages the proteins of the CD40 signalosome. Studies to determine if LMP1 could be used for immunotherapy led to the following conclusions: (1) LMP1 mRNA directly activated human dendritic cells (DCs), showing its potential as an adjuvant for mRNA vaccines; (2) Adenovirus (Ad)-delivered LMP1 strongly enhanced vaccine-induced CD8+ T cell responses in mice, indicating that LMP1 may enhance Ad-based oncolytic therapies; (3) lentiviruses incorporating LMP1 became strong activators of DCs in vitro; and (4) DNA vaccines incorporating LMP1 protected mice from tumor challenge in a B16F10 melanoma metastasis model. These data show that the LMP1 nucleic acid sequence is a portable genetic adjuvant with broad applicability to tumor immunotherapy. In related studies, the membrane clustering N-terminal domain of LMP1 was fused to Interferon-beta Promoting Stimulator-1 (IPS-1, also called MAVS, VISA, or Cardif), a protein that requires membrane clustering to become activated. This fusion protein acts independently of cyclic dinucleotides (CDN) to activate downstream mediators of the STING pathway. Vaccination of mice with Ad expressing antigen plus LMP1-IPS-1 resulted in complete protection from challenge with Vaccinia-antigen virus (>1 million-fold protection). These data suggest that LMP1-IPS-1 combined with gene delivery technologies may supplant the need for small molecule CDNs for STING pathway activation in immuno-oncology. Citation Format: Richard S. Kornbluth, Sachin Gupta, James M. Termini, Elizabeth Guirado, Geoffrey W. Stone. Immune activation by LMP1 CD40 pathway and LMP1-IPS-1 STING pathway activators [abstract]. In: Proceedings of the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; 2016 Sept 25-28; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(11 Suppl):Abstract nr B062." @default.
• W2547932707 created "2016-11-11" @default.
• W2547932707 creator A5028861349 @default.
• W2547932707 creator A5036809089 @default.
• W2547932707 creator A5041221134 @default.
• W2547932707 creator A5065148141 @default.
• W2547932707 creator A5072303198 @default.
• W2547932707 date "2016-10-31" @default.
• W2547932707 modified "2023-09-26" @default.
• W2547932707 title "Abstract B062: Immune activation by LMP1 CD40 pathway and LMP1-IPS-1 STING pathway activators" @default.
• W2547932707 doi "https://doi.org/10.1158/2326-6066.imm2016-b062" @default.
• W2547932707 hasPublicationYear "2016" @default.
• W2547932707 type Work @default.
• W2547932707 sameAs 2547932707 @default.
• W2547932707 citedByCount "0" @default.
• W2547932707 crossrefType "proceedings-article" @default.
• W2547932707 hasAuthorship W2547932707A5028861349 @default.
• W2547932707 hasAuthorship W2547932707A5036809089 @default.
• W2547932707 hasAuthorship W2547932707A5041221134 @default.
• W2547932707 hasAuthorship W2547932707A5065148141 @default.
• W2547932707 hasAuthorship W2547932707A5072303198 @default.
• W2547932707 hasConcept C159047783 @default.
• W2547932707 hasConcept C167672396 @default.
• W2547932707 hasConcept C203014093 @default.
• W2547932707 hasConcept C2776090121 @default.
• W2547932707 hasConcept C2777701055 @default.
• W2547932707 hasConcept C502942594 @default.
• W2547932707 hasConcept C86803240 @default.
• W2547932707 hasConcept C8891405 @default.
• W2547932707 hasConceptScore W2547932707C159047783 @default.
• W2547932707 hasConceptScore W2547932707C167672396 @default.
• W2547932707 hasConceptScore W2547932707C203014093 @default.
• W2547932707 hasConceptScore W2547932707C2776090121 @default.
• W2547932707 hasConceptScore W2547932707C2777701055 @default.
• W2547932707 hasConceptScore W2547932707C502942594 @default.
• W2547932707 hasConceptScore W2547932707C86803240 @default.
• W2547932707 hasConceptScore W2547932707C8891405 @default.
• W2547932707 hasLocation W25479327071 @default.
• W2547932707 hasOpenAccess W2547932707 @default.
• W2547932707 hasPrimaryLocation W25479327071 @default.
• W2547932707 hasRelatedWork W1545631997 @default.
• W2547932707 hasRelatedWork W1985270499 @default.
• W2547932707 hasRelatedWork W2024728794 @default.
• W2547932707 hasRelatedWork W2061518046 @default.
• W2547932707 hasRelatedWork W2065365555 @default.
• W2547932707 hasRelatedWork W2155629317 @default.
• W2547932707 hasRelatedWork W2317889432 @default.
• W2547932707 hasRelatedWork W2331783064 @default.
• W2547932707 hasRelatedWork W2402045597 @default.
• W2547932707 hasRelatedWork W2547395795 @default.
• W2547932707 hasRelatedWork W2566478821 @default.
• W2547932707 hasRelatedWork W2886377137 @default.
• W2547932707 hasRelatedWork W2912608618 @default.
• W2547932707 hasRelatedWork W2914168980 @default.
• W2547932707 hasRelatedWork W2946170821 @default.
• W2547932707 hasRelatedWork W2966262010 @default.
• W2547932707 hasRelatedWork W2991293392 @default.
• W2547932707 hasRelatedWork W3177450153 @default.
• W2547932707 hasRelatedWork W3201853605 @default.
• W2547932707 hasRelatedWork W975803505 @default.
• W2547932707 isParatext "false" @default.
• W2547932707 isRetracted "false" @default.
• W2547932707 magId "2547932707" @default.
• W2547932707 workType "article" @default.